The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Neuromyelitis Optica Spectrum Disorder (NMOSD)

An autoimmune astrocytopathy mediated by antibodies against aquaporin-4, characterized by optic neuritis, longitudinally extensive transverse myelitis, and brainstem syndromes, requiring early immunotherapy to prevent disability.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Nöroloji department. Book Appointment →

What is Neuromyelitis Optica Spectrum Disorder (NMOSD)?

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune astrocytopathy mediated predominantly by antibodies against aquaporin-4 water channels expressed on astrocytes, with selective vulnerability of optic nerves, spinal cord, and circumventricular brain regions.

Diagnostic criteria (2015 international panel) incorporate AQP4-IgG seropositivity, six core clinical features (optic neuritis, acute myelitis, area postrema syndrome, brainstem, diencephalic, cerebral syndromes), and characteristic MRI findings; a subset of seronegative patients harbor MOG antibodies and are now classified separately as MOGAD.

Treatment is divided into acute attack therapy (high-dose intravenous methylprednisolone followed by plasma exchange in steroid-refractory cases) and long-term immunosuppression with rituximab, mycophenolate mofetil, azathioprine, eculizumab (anti-C5), satralizumab (anti-IL-6R), or inebilizumab (anti-CD19), individualized by severity and comorbidity.

Symptoms

Acute or subacute unilateral or bilateral painful visual loss (optic neuritis), often more severe than multiple sclerosis-related
Longitudinally extensive transverse myelitis with bilateral motor weakness, sensory level, and bowel and bladder dysfunction
Intractable hiccups, nausea, or vomiting due to area postrema syndrome
Brainstem symptoms: diplopia, vertigo, dysarthria, or facial sensory changes
Diencephalic syndromes: hypersomnia, hypothermia, hyponatremia, anorexia
Cognitive impairment or seizures from cerebral white matter or cortical lesions

Risk Factors

Female sex (9:1 female to male ratio for AQP4-IgG-positive disease)
Adult onset, typically in the third to fifth decades
African and Asian ancestry have higher prevalence and severity
Coexistent autoimmune disorders: systemic lupus erythematosus, Sjogren syndrome, autoimmune thyroiditis
Family history of autoimmune disease
Recent viral or bacterial infection or pregnancy in some seronegative cases

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Acute painful unilateral or bilateral visual loss — emergency neurology and ophthalmology assessment
  • Acute spinal cord syndrome with bilateral weakness, sensory level, or bowel/bladder dysfunction
  • Intractable hiccups, nausea, or vomiting persisting for more than 48 hours without gastrointestinal explanation
  • New brainstem or cerebellar symptoms in a patient with prior optic neuritis
  • Established NMOSD with new symptoms suggestive of relapse — urgent admission for high-dose corticosteroids and possible plasma exchange

Treatment Methods

01
Acute attack: high-dose intravenous methylprednisolone 1 g daily for 5 days, followed by oral taper; plasma exchange (5 to 7 sessions) for severe or steroid-refractory attacks
02
Long-term immunosuppression with rituximab (anti-CD20) every 6 months, mycophenolate mofetil, or azathioprine — historic standards
03
Eculizumab (terminal complement C5 inhibitor) for AQP4-IgG-positive patients with high relapse risk; intravenous infusion every 2 weeks with meningococcal vaccination prophylaxis
04
Satralizumab (humanized anti-IL-6 receptor monoclonal antibody) administered subcutaneously every 4 weeks, effective in AQP4-IgG-positive disease
05
Inebilizumab (anti-CD19 monoclonal antibody) intravenously twice yearly for AQP4-IgG-positive disease; symptomatic management of spasticity, neuropathic pain, bladder dysfunction, and rehabilitation

Which Department to Visit?

You can visit our Nöroloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Nöroloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Headache and Migraine

Nöroloji

What you need to know about headache types, migraine attacks, and triggering factors.

Low Back Pain

Nöroloji

Learn about the most common causes of low back pain, risk factors, and appropriate treatment approaches.

Neck Pain and Cervical Disc Herniation

Nöroloji

Learn about the symptoms and treatment options for cervical disc herniation and problems in the neck region.

Epilepsy

Nöroloji

Accurate information about epilepsy, types of seizures, and recommendations for patients and families.

Parkinson Disease

Nöroloji

Parkinson disease is caused by progressive degeneration of dopaminergic neurons and alpha-synuclein accumulation; well-timed therapy substantially improves function and quality of life.

Alzheimer's Disease and Dementia

Nöroloji

Information about early signs, diagnosis, and the care process for Alzheimer's and other types of dementia.

Multiple Sclerosis (MS)

Nöroloji

What is multiple sclerosis, who is at risk, and which treatments are applied?

Stroke

Nöroloji

What is stroke, what are the FAST signs, and why is emergency intervention critical?

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.